IPA's strategy melds AI-driven analytics with specialised wet-lab methodologies to design and optimise antibodies.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and ...

New research from the Perelman School of Medicine at the University of Pennsylvania suggests that a combination of messenger ...

ImmunoPrecise Antibodies Ltd., an AI-powered antibody company, has partnered with RIBOPRO, a technology provider specializing ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

By adjusting the fat levels in mRNA-based drugs, researchers have found a way to bypass the liver and go straight to the ...

RIBOPRO is a Netherlands-based technology and service provider specializing in mRNA and lipid nanoparticle (LNP) technologies. Founded in 2020, RIBOPRO develops and manufactures high-quality mRNA ...

RIBOPRO is a Netherlands-based technology and service provider specializing in mRNA and lipid nanoparticle (LNP) technologies. Founded in 2020, RIBOPRO develops and manufactures high-quality mRNA and ...

Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...